NDAORALTABLETPriority Review
Approved
Jul 2021
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
27
Data completeness
7/8 — Comprehensive
Priority Review
KERENDIA (finerenone) by Bayer is mineralocorticoid receptor antagonists [moa]. Approved for nonsteroidal mineralocorticoid-receptor antagonist [epc]. First approved in 2021.
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KERENDIA (finerenone) is a nonsteroidal mineralocorticoid receptor antagonist approved in 2021 for chronic kidney disease patients. It works by blocking aldosterone signaling to reduce glomerular filtration rate decline and proteinuria. The oral small-molecule tablet represents a new therapeutic class addressing a key complication of diabetes and hypertension.
$0.27BPart D
Peak9.1 years to LOEPeak lifecycle stage indicates mature commercial infrastructure with established field teams, likely 200–400+ headcount supporting a stable revenue base with limited growth upside.
Mechanism of Action
Mineralocorticoid Receptor Antagonists
Pharmacologic Class:
Nonsteroidal Mineralocorticoid-Receptor Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (27)
A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction
Started Jun 2026
117 enrolled
Left Ventricular Systolic DysfunctionHeart Failure (Pediatric)
An Observational Study, Called FINEXPLORER, to Learn More About How Well Finerenone Works in Adults in Spain With Chronic Kidney Disease (CKD) Linked to Type 2 Diabetes, by Looking at Changes in a CKD Risk Score
Started May 2026
500 enrolled
Chronic Kidney DiseaseType 2 Diabetes Mellitus
A Study to Learn More About How Safe Finerenone is and How Well it Works in Adults With Chronic Heart Failure in South Korea
Started Dec 2025
300 enrolled
Chronic Heart Failure
Finerenone and Cardiac Remodeling
Started Dec 2025
156 enrolled
Heart Failure
An Observational Study Called FINE-REAL Korea to Learn More About the Use of the Drug Finerenone in People With Chronic Kidney Disease and Type 2 Diabetes in a Routine Medical Care Setting in South Korea
Started Nov 2025
500 enrolled
Chronic Kidney DiseaseType 2 Diabetes Mellitus
Worked on KERENDIA at Bayer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.